Delivery Order SPE2DB22D9367-SPE2DB25FSZ38
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,735.58 to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose in 2-pen/mL formulation on August 25, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 26, 2025, represents a pharmaceutical supply requirement with performance taking place in Conshohocken, Pennsylvania. The award was made without set-aside designation to DMS Pharmaceutical Group, a woman-owned small business...
- On August 20, 2025, the Defense Logistics Agency awarded a delivery order valued at $10,461.10 to DMS Pharmaceutical Group Inc. for the supply of Cosentyx (secukinumab) 300 mg pen 2 mL injections. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The contract does not utilize a set-aside designation, and the pharmaceutical products will be...
- The Defense Logistics Agency awarded a firm fixed price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide Cosentyx (secukinumab) 300 mg/2 mL injectable pens. The contract has a potential value of $3,382.36 and a completion date of January 3, 2024. DMS Pharmaceutical Group is a pharmaceutical wholesaler that holds multiple federal contracts and Indefinite Delivery Vehicles (IDVs) to supply a variety of pharmaceutical and medical products to support...
- The Defense Logistics Agency awarded a $16.8K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cosentyx (secukinumab) 300 mg pen injections. The order, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed-price delivery under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500 million and valid through November...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The order is for the delivery of Cosentyx (secukinumab) 300 mg pens, with a completion date of January 12, 2024 and a potential value of $3,382.36. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that provides a wide range of brand name and generic prescription and over-the-counter drug supplies to the U.S. Department of...
- This federal contract award is for the delivery of Cosentyx (secukinumab) 300 mg pens to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense (DoD). The contract, valued at $3,382.36, was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order with no set-aside designation, running from the award date of July 30, 2024 through the ultimate...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $3,382.36, is for the delivery of Cosentyx (secukinumab) 300 mg pens to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $13,456.01 by the Defense Logistics Agency (DLA) on August 13, 2025. The contract calls for the delivery of Cosentyx Unoready 300 mg pen 2ml pharmaceutical product to a location in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. This delivery order was issued without a set-aside designation,...
- The Defense Logistics Agency awarded a firm fixed price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide Cosentyx 300 mg pens. The potential value of this delivery order is $3,382.36 with a completion date of January 3, 2024. DMS Pharmaceutical Group is an experienced pharmaceutical wholesaler that holds multiple contracts and indefinite delivery vehicles with the Defense Logistics Agency to supply a variety of medical products and prescription...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $16,800.32 firm fixed-price contract is for the delivery of Cosentyx, a prescription medication, and has an ultimate completion date of April 30, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency...
- SPE2DB22D9367Indefinite Delivery Contract
- SPE2DB22D9367-SPE2DB25FSZ38Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,200.08 to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300 mg pen 2 ml on August 25, 2025, with completion expected by August 26, 2025. This firm fixed-price delivery order represents a specific pharmaceutical requisition issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, valued at $499.999 billion and extending through November 2026. The award carries no set-aside designation, and the place of performance is Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its headquarters operations. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, has established itself as a critical supplier in the federal pharmaceutical supply chain, particularly for Department of Defense healthcare facilities. The company's core mission involves distributing branded and generic prescription drugs, biologics, and medical consumables to military and federal healthcare systems nationwide. Cosentyx, an immunosuppressant biologic used primarily for autoimmune conditions including psoriasis, psoriatic arthritis, and ankylosing spondylitis, represents the type of specialized pharmaceutical product consistent with DMS Pharmaceutical Group's portfolio of deliveries to military health facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 8/25/25 |